Search details
1.
Integrative clinical genomics of advanced prostate cancer.
Cell
; 161(5): 1215-1228, 2015 May 21.
Article
in English
| MEDLINE | ID: mdl-26000489
2.
Integrative Clinical Genomics of Advanced Prostate Cancer.
Cell
; 162(2): 454, 2015 Jul 16.
Article
in English
| MEDLINE | ID: mdl-28843286
3.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate
; 84(3): 292-302, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37964482
4.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37980367
5.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
J Urol
; 211(4): 526-532, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38421252
6.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
J Urol
; 211(4): 509-517, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38421253
7.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
J Urol
; 211(4): 518-525, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38421243
8.
Prostate Cancer, Version 3.2024.
J Natl Compr Canc Netw
; 22(3): 140-150, 2024 04.
Article
in English
| MEDLINE | ID: mdl-38626801
9.
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Prostate
; 83(3): 227-236, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36382533
10.
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
Cancer Immunol Immunother
; 72(3): 775-782, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-35998004
11.
Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
Ann Surg Oncol
; 30(3): 1312-1326, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36335273
12.
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(10): 1067-1096, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37856213
13.
Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
Curr Opin Urol
; 33(5): 396-403, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37497748
14.
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.
Qual Life Res
; 32(11): 3209-3221, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37410340
15.
Germline genetics of prostate cancer.
Prostate
; 82 Suppl 1: S3-S12, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35657157
16.
A Patient-Centered Approach to Research Prioritization in Prostate Cancer.
J Urol
; 208(2): 277-283, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35394343
17.
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
J Natl Compr Canc Netw
; 20(12): 1288-1298, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36509074
18.
Barriers and facilitators of germline genetic evaluation for prostate cancer.
Prostate
; 81(11): 754-764, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34057231
19.
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Prostate
; 81(16): 1382-1389, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34516663
20.
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Prostate
; 81(7): 433-439, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33792945